Promising Drug Candidate May Overcome Drug-Resistant Lung Cancer
Researchers have developed a promising new drug candidate, EAI-432, to treat drug-resistant non-small cell lung cancers.
Complete the form below to unlock access to ALL audio articles.
Researchers at Dana-Farber Cancer Institute have developed a promising new drug candidate, EAI-432, to treat non-small cell lung cancers (NSCLC) driven by mutations in the EGFR gene, particularly the L858R mutation, which is present in about one-third of NSCLC patients. EAI-432, an allosteric inhibitor with high selectivity for the L858R mutation and subsequent clinical resistance mutations, provides a potential new approach for NSCLC patients for whom there are currently no approved targeted therapies. Combination with the current frontline therapy may also lead to enhanced outcomes, delaying the emergence of resistance in that patient population.
Approved EGFR inhibitors bind to the active site of the EGFR target, known as the ATP binding pocket. Unlike other fourth-generation compounds in development, EAI-432, binds to a site separate from the active ATP pocket on EGFR, causing conformational changes and effectively inhibiting it.
Preclinical studies presented at the AACR-NCI-EORTC meeting in October show that EAI-432 can co-bind with other EGFR-targeted inhibitors, representing a potential strategy for improving patient outcomes. In the poster presentation, Dana-Farber scientists shared that EAI-432 co-binds with osimertinib, a third-generation EGFR inhibitor, which is the standard-of-care therapy for patients with EGFR mutations. EAI-432 has good oral pharmacokinetics, is brain-penetrant, and has demonstrated good efficacy in mouse xenograft models.
"Since EAI-432 binds in a different pocket to other EGFR inhibitors, it should address many of the resistance mechanisms that emerge and represents a potential new therapy for patients who have become resistant to the standard of care," says David Scott, PhD, director, Medicinal Chemistry Core at Dana-Farber. The compound may also be useful in combination with current EGFR inhibitors like osimertinib as initial treatment in patients with the L858R mutation.
Osimertinib is the leading treatment for patients with EGFR-mutant NSCLC, but resistance mutations including L858R/C797S and L858R/T790M/C797S have emerged in the clinic. No targeted therapies are approved for NSCLC patients with these mutations, representing a significant unmet need.
"EAI-432 has potential for NSCLC patients with these mutations who have developed resistance to osimertinib," explains Pasi Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber, adding that there are no allosteric EGFR inhibitors in the clinic at this time. "Only the allosteric approach allows for double-drugging of the mutant receptor, a potentially significant advance for the patient population with emerging mutation status."
The path to develop EAI-432 at Dana-Farber began over 15 years ago and has involved both academic and industry collaborations. It now centers in the laboratories of Michael Eck, David Scott, and Pasi Jänne. Major funding and scientific input to support the IND-enabling studies has been provided by the Mark Foundation for Cancer Research (MFCR), with additional funding from the Dana-Farber Accelerator program and the Blavatnik Family Foundation.
EAI-432 is a fourth-generation, orally bioavailable, CNS-penetrant allosteric EGFR inhibitor designed to target L858R EGFR-mutated cancers as a monotherapy and in combination with standard-of-care EGFR inhibitors. EAI-432 is potent against mutants resistant to first-generation (gefitinib) and third-generation (osimertinib) agents. EAI-432 is currently progressing through IND-enabling studies, to be completed in the second half of 2024.
- EAI-432, an allosteric inhibitor, offers a new approach to targeting mutant-EGFR driven NSCLC
- By binding outside the ATP pocket, it co-binds with the current standard-of-care third generation EGFR inhibitor, and represents a unique double-drugging strategy
- EAI-432 was developed specifically for the L858R mutation, with selectivity over wild-type EGFR
- IND-enabling studies are on track to be completed in the second half of 2024
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.